Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19
Muhanna Kazempour, Hossein Izadi, Arezoo Chouhdari, Morteza Rezaeifard
doi:10.22037/ijpr.2021.114567.14917
Metronidazole (MTZ) can decrease the levels of several cytokines. This research aimed at the investigation of the anti-inflammatory impact of MTZ in COVID-19. A randomized, singleblind clinical trial for comparing the anti-inflammatory effect of MTZ in two eligible groups of adult patients with lower respiratory tract involvement due to Covid-19 treated with a standard national method with or without MTZ was performed. Inflammatory markers were measured as the primary outcome in two groups. Oxygen saturation, length of hospital stays, and mortality of patients were evaluated as secondary outcomes. Among 44 patients with lower respiratory tract due to Covid-19, 20(45.5%) were randomly allocated in group A with the current standard treatment plus the MTZ tablet for 7 days orally and 24 (54.5%) in group B with the current standard treatment. The mean of ESR in group A was statistically significantly lower than that of group B on the seventh day (A: 38.25 ± 18.75 vs. B: 47.67 ± 26.41, p = 0.02). Moreover, the mean of IL6 diminished significantly in both A (p = 0.01) and B (p = 0.01) groups on the seventh day compared to the first day. The decrease of TNF was not significant in any of the groups A (p = 0.3) and B (p = 0.4) from the 7 th day to the first day. No significant difference was not found between group A and group B groups on the CRP level (p = 0.1). Findings of this study showed the anti-inflammatory impact of MTZ in the patient with lower respiratory inflammation due to COVID-19.
Conflicts of Interest It is declared that there are not any conflicts of interest in the present research.
References
Bai, Yao, Wei, Tian, Jin et al., Presumed asymptomatic carrier transmission of COVID-19, JAMA
Borba, Val, Sampaio, Alexandre, Melo et al., Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Network Open
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N. Eng. J. Med
Ceruelos, Romero-Quezada, Ledezma, Contreras, Therapeutic uses of metronidazole and its side effects: an update, Eur. Rev. Med. Pharmacol. Sci
Fararjeh, Mohammad, Bustanji, Alkhatib, Abdalla, Evaluation of immunosuppression inducedby metronidazole in Balb/c mice and human peripheral blood lymphocytes, Int. Immunopharmacol
Gao, Li, Han, Li, Wu et al., Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19, J. Med. Virol
Gharebaghi, Heidary, Moradi, Parvizi, Metronidazole; a potential novel addition to the COVID-19 treatment regimen, Arch. Acad. Emerg. Med
Helmy, Fawzy, Elaswad, Sobieh, Kenney et al., The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control, J. Clin. Med
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study, Clin. Med
Lefebvre, Hesseltine, The peripheral white blood cells and metronidazole, JAMA
Rizzo, Paolillo, Guida, Annunziata, Bevilacqua et al., Effect of metronidazole and modulation of cytokine production on human periodontal ligament cells, Int. Immunopharmacol
Seyedhamzeh, Far, Ardestani, Javanshir, Aliabadi et al., Dose COVID-19 uncovered a new feature of Metronidazole Drug, Chemrxiv
Shakir, Javeed, Ashraf, Riaz, Metronidazole and the immune system, Die Pharmazie-Int. J. Pharm. Sci. Res
Shimabukuro-Vornhagen, Gödel, Subklewe, Stemmler, Schlößer et al., Cytokine release syndrome, J. ImmunoTher. Cancer
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: A clinicaltherapeutic staging proposal, J. Heart Lung Transplant
Sun, Wang, Cai, Cytokine storm intervention in the early stages of COVID-19 pneumonia, Cytokine Growth Factor Rev
Yudin, Landers, Meyn, Hillier, Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial, Obstet. Gynecol
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
DOI record:
{
"DOI": "10.22037/ijpr.2021.114567.14917",
"URL": "https://doi.org/10.22037/ijpr.2021.114567.14917",
"author": [
{
"family": "Kazempour",
"given": "Muhanna"
},
{
"family": "Izadi",
"given": "Hossein"
},
{
"family": "Chouhdari",
"given": "Arezoo"
},
{
"family": "Rezaeifard",
"given": "Morteza"
}
],
"container-title": "Iranian Journal of Pharmaceutical Research",
"container-title-short": "IJPR",
"issue": "3",
"issued": {
"date-parts": [
[
2021,
9
]
]
},
"journalAbbreviation": "IJPR",
"language": "eng",
"publisher": "School of Pharmacy, Shahid Beheshti University of Medical Sciences",
"publisher-place": "IR",
"title": "Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19",
"type": "article-journal",
"volume": "20"
}
